Literature DB >> 16394043

Aggressive surgical effort and improved survival in advanced-stage ovarian cancer.

Giovanni D Aletti1, Sean C Dowdy, Bobbie S Gostout, Monica B Jones, C Robert Stanhope, Timothy O Wilson, Karl C Podratz, William A Cliby.   

Abstract

OBJECTIVE: Residual disease after initial surgery for ovarian cancer is the strongest prognostic factor for survival. However, the extent of surgical resection required to achieve optimal cytoreduction is controversial. Our goal was to estimate the effect of aggressive surgical resection on ovarian cancer patient survival.
METHODS: A retrospective cohort study of consecutive patients with International Federation of Gynecology and Obstetrics stage IIIC ovarian cancer undergoing primary surgery was conducted between January 1, 1994, and December 31, 1998. The main outcome measures were residual disease after cytoreduction, frequency of radical surgical resection, and 5-year disease-specific survival.
RESULTS: The study comprised 194 patients, including 144 with carcinomatosis. The mean patient age and follow-up time were 64.4 and 3.5 years, respectively. After surgery, 131 (67.5%) of the 194 patients had less than 1 cm of residual disease (definition of optimal cytoreduction). Considering all patients, residual disease was the only independent predictor of survival; the need to perform radical procedures to achieve optimal cytoreduction was not associated with a decrease in survival. For the subgroup of patients with carcinomatosis, residual disease and the performance of radical surgical procedures were the only independent predictors. Disease-specific survival was markedly improved for patients with carcinomatosis operated on by surgeons who most frequently used radical procedures compared with those least likely to use radical procedures (44% versus 17%, P < .001).
CONCLUSION: Overall, residual disease was the only independent predictor of survival. Minimizing residual disease through aggressive surgical resection was beneficial, especially in patients with carcinomatosis. LEVEL OF EVIDENCE: II-2.

Entities:  

Mesh:

Year:  2006        PMID: 16394043     DOI: 10.1097/01.AOG.0000192407.04428.bb

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  108 in total

1.  Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.

Authors:  Keith L Knutson; Matthew J Maurer; Claudia C Preston; Kirsten B Moysich; Krista Goergen; Kieran M Hawthorne; Julie M Cunningham; Kunle Odunsi; Lynn C Hartmann; Kimberly R Kalli; Ann L Oberg; Ellen L Goode
Journal:  Cancer Immunol Immunother       Date:  2015-08-23       Impact factor: 6.968

2.  Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182.

Authors:  Neil S Horowitz; Austin Miller; Bunja Rungruang; Scott D Richard; Noah Rodriguez; Michael A Bookman; Chad A Hamilton; Thomas C Krivak; G Larry Maxwell
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

3.  Trends in treatment of advanced epithelial ovarian cancer in the Medicare population.

Authors:  Melissa M Thrall; Heidi J Gray; Rebecca Gaston Symons; Noel S Weiss; David R Flum; Barbara A Goff
Journal:  Gynecol Oncol       Date:  2011-04-15       Impact factor: 5.482

4.  [Peritoneal carcinomatosis in ovarian cancer. Methods and treatment results].

Authors:  J Pfisterer; P Harter; F Hilpert; A du Bois
Journal:  Chirurg       Date:  2007-12       Impact factor: 0.955

5.  The Influence of "Omental Cake" Presence on the Completeness of Cytoreduction in Advanced-stage Ovarian Cancer.

Authors:  Nicolae Bacalbasa; Camelia Diaconu; Laura Iliescu; Cornel Savu; Ovidiu Gabriel Bratu; Ciprian Bolca; Dragos Cretoiu; Alexandru Filipescu; Simona Dima; Cristian Balalau; Irina Balescu
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 6.  Operative management of primary epithelial ovarian cancer.

Authors:  Mario M Leitao; Dennis S Chi
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

Review 7.  Review of methodological challenges in comparing the effectiveness of neoadjuvant chemotherapy versus primary debulking surgery for advanced ovarian cancer in the United States.

Authors:  Ashley L Cole; Anna E Austin; Ryan P Hickson; Matthew S Dixon; Emma L Barber
Journal:  Cancer Epidemiol       Date:  2018-05-25       Impact factor: 2.984

8.  Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Ramez N Eskander; James Kauderer; Krishnansu S Tewari; Robert S Mannel; Robert E Bristow; David M O'Malley; Stephen C Rubin; Gretchen E Glaser; Chad A Hamilton; Keiichi Fujiwara; Warner K Huh; Frederick Ueland; Jean-Marie Stephan; Robert A Burger
Journal:  Gynecol Oncol       Date:  2018-03-15       Impact factor: 5.482

9.  Comparison of Platinum-based Neoadjuvant Chemotherapy and Primary Debulking Surgery in Patients with Advanced Ovarian Cancer.

Authors:  Manizheh Sayyah-Melli; Gita Kashi Zonoozi; Shahryar Hashemzadeh; Ali Esfahani; Elaheh Ouladehsahebmadarek; Mehry Jafary Shobeiry; Parvin Mostafa Garabaghi; Azhough Ramin
Journal:  J Obstet Gynaecol India       Date:  2013-08-14

10.  Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma.

Authors:  Sean C Dowdy; Ralitsa T Loewen; Giovanni Aletti; Simone S Feitoza; William Cliby
Journal:  Gynecol Oncol       Date:  2008-04-01       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.